Company intelligence / Profile preview

Naltrexone Therapeutics Inc.

Vancouver, Canada

Ownership: Private
Development stage: Other

Overview

Holds IP for transdermal delivery of naltrexone, aimed at improving bioavailability, regulating dosage, and reducing GI side effects for treating substance use disorders and potentially long COVID. No clinical results reported.

Therapeutic areas: PsychiatryInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

naltrexone transdermal patch

Preclinical

Partnerships

LOVE Pharma Co.

Beyond the preview

Go deeper on Naltrexone Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naltrexone Therapeutics Inc..

Explore the full profile